CN113481175A - Ethylenic bond reductase mutant with improved activity and stereoselectivity as well as encoding gene and application thereof - Google Patents
Ethylenic bond reductase mutant with improved activity and stereoselectivity as well as encoding gene and application thereof Download PDFInfo
- Publication number
- CN113481175A CN113481175A CN202110674324.3A CN202110674324A CN113481175A CN 113481175 A CN113481175 A CN 113481175A CN 202110674324 A CN202110674324 A CN 202110674324A CN 113481175 A CN113481175 A CN 113481175A
- Authority
- CN
- China
- Prior art keywords
- ala
- gly
- glu
- leu
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/002—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by oxidation/reduction reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses an olefinic bond reductase mutant with improved activity and stereoselectivity, a coding gene and application thereof, wherein the olefinic bond reductase mutant comprises an olefinic bond reductase mutant Y84A, Y84V, Y84L, Y84I, Y84T and Y84C which are formed by mutating 84 th amino acid residue by using a wild type olefinic bond reductase OYE2p shown in SEQ ID NO.1 as a template, and the amino acid sequence is shown in SEQ ID NO. 3-8. The mutant of the olefinic bond reductase provided by the invention can catalyze citral to prepare (R) -citronellal with high activity and high stereoselectivity, has the characteristics of economy, environmental protection and high chiral selectivity, and provides a potential biocatalyst for industrial production of (R) -citronellal.
Description
Technical Field
The invention belongs to the technical field of bioengineering, and particularly relates to an olefinic bond reductase mutant with improved activity and stereoselectivity, and a coding gene and application thereof.
Background
The (R) -Citronellal ((R) - (+) -Citronellal) is chemically (3R) -3, 7-dimethyl-6-octenal, has a chemical structural formula shown as (I), is an important spice and a medical intermediate, can be used for blending flavors of foods, daily necessities and the like, and can also be used as a raw material for synthesizing L-menthol and vitamin E. At present, (R) -citronellal is mainly obtained by separating and extracting natural essential oil, and can also be prepared by catalytic hydrogenation of citral through a metal catalyst.
Compared with other methods, the method for synthesizing (R) -citronellal by catalyzing citral through the olefinic bond reductase and carrying out asymmetric reduction has the advantages of environmental friendliness, mild reaction conditions, high product stereoselectivity and the like. The currently reported olefinic bond reductases capable of catalyzing citral to generate (R) -citronellal are few, and the catalytic activity is low. Stewart et al obtained an olefinic bond reductase OYE2.6 from Pichia stipitis which catalyzes the formation of (R) -citronellal from 150mM E-citral within 5.75h with a product ee value of 98% [ Chemical Communications,2010,46(45):8558- ] 8560; however, the substrate E-citral is obtained by separating citral (mixture of E, Z-citral). Hauer et al have engineered an olefinic bond reductase NCR derived from Zymomonas mobilis by means of protein engineering, and finally the enantioselectivity of the mutant strain W66A to E-citral is reversed from 99% (S) to 46% (R), but the enantioselectivity to Z-citral is only 88% (S), so that the requirement for producing (R) -citronellal is difficult to meet. Therefore, the development of an ethylenic reductase capable of catalyzing citral to (R) -citronellal with high activity and high selectivity has important industrial application value.
Disclosure of Invention
The invention aims to provide an olefinic bond reductase mutant with improved activity and stereoselectivity, a coding gene and application thereof, so as to solve the problems of low stereospecific activity and low stereoselectivity in the existing technology for synthesizing (R) -citronellal by catalytic catalysis of olefinic bond reductase.
In order to solve the technical problems, the invention adopts the following technical scheme:
according to a first aspect of the present invention, there is provided an olefinic bond reductase mutant with improved activity and stereoselectivity, comprising an olefinic bond reductase mutant obtained by mutating amino acid 84 as follows, wherein the olefinic bond reductase mutant is OYE2p as a template, and has an amino acid sequence as shown in SEQ ID No.1 and a nucleotide sequence as shown in SEQ ID No. 2: an ethylenic reductase mutant Y84A (SEQ ID NO.3) in which tyrosine Y at position 84 is mutated to alanine A; an olefinic bond reductase mutant Y84V (SEQ ID NO.4) in which tyrosine Y at position 84 is mutated to valine V; an ethylenic reductase mutant Y84L (SEQ ID NO.5) in which tyrosine Y at position 84 is mutated to leucine L; an olefinic bond reductase mutant Y84I (SEQ ID NO.6) in which the tyrosine Y at position 84 is mutated into isoleucine I; an ethylenic reductase mutant Y84T (SEQ ID NO.7) in which tyrosine Y at position 84 is mutated to threonine T; an ethylenic reductase mutant Y84C (SEQ ID NO.8) in which tyrosine Y at position 84 is mutated to cysteine C.
According to the invention, a deposited olefinic bond reductase OYE2p (derived from Saccharomyces cerevisiae YJM1341, see document Bioresource. bioprocess. (2018)5:9) is constructed at a laboratory early stage and used as a template, the amino acid sequence of the olefinic bond reductase is shown as SEQ ID No.1, the nucleotide sequence is shown as SEQ ID No.2, and the olefinic bond reductase mutant with obviously improved catalytic activity, stereoselectivity and the like is obtained by carrying out site-directed mutagenesis on the olefinic bond reductase.
According to a second aspect of the present invention, there is provided a gene encoding an olefinic bond reductase mutant having improved enzymatic activity and stereoselectivity as described above, the gene encoding an amino acid sequence shown in the olefinic bond reductase mutant as described above.
Particularly preferably, the invention provides an olefinic bond reductase mutant Y84V with improved enzyme activity and stereoselectivity, and the nucleotide sequence of the coding gene is shown as SEQ ID NO. 9.
According to the third aspect of the invention, the recombinant gene engineering bacteria containing the coding gene of the olefinic bond reductase mutant with improved enzyme activity and stereoselectivity are also provided. The host cell may be any of the various conventional host cells in the art, and preferably, the host cell is E.coli BL21(DE 3).
According to the fourth aspect of the invention, the application of the ethylenic reductase mutant in catalyzing citral to prepare (R) -citronellal is also provided.
The application takes engineering bacteria containing olefinic bond reductase mutant coding genes, thalli obtained by centrifugation after fermentation culture, thalli immobilized cells, enzyme extracted after ultrasonic disruption of the thalli, immobilized enzyme or pure enzyme as a catalyst, citral as a substrate, a buffer solution with the pH value of 7-9 as a reaction medium, and the reaction is carried out under the conditions of 20-40 ℃, 150-300rpm, and after the reaction is finished, the reaction liquid is separated and purified to obtain (R) -citronellal.
It should be understood that the olefinic bond reductase mutant of the present invention can be used in the form of whole cells of the engineered bacterium, crude enzyme without purification, or partially purified or completely purified enzyme. The mutant ethylenic reductase of the present invention may also be prepared into biocatalysts in the form of immobilized enzymes or immobilized cells using immobilization techniques known in the art.
Preferably, the concentration of the substrate is 50-200mM, the concentration of the glucose is 55-220mM, the dosage of the crude enzyme powder of the ethylenic bond reductase is 2U/mL by the enzyme activity, and the dosage of the crude enzyme powder of the glucose dehydrogenase is 3U/mL by the enzyme activity.
Preferably, the reaction medium is PBS buffer solution with pH value of 8.5, and the temperature of the catalytic reaction is 30 ℃.
Preferably, the crude enzyme powder of the olefinic bond reductase is a lyophilized olefinic bond reductase mutant Y84V.
The medium used for recombinant expression of the transformant may be a medium which allows the transformant to grow and produce the ethylenic reductase of the present invention in the art, and is preferably an LB medium: 10g/L of peptone, 10g/L of sodium chloride, 5g/L of yeast extract and 7.0 of pH.
The culture method and culture conditions are not particularly limited as long as the transformant can grow and express the ethylenic reductase. The method specifically comprises the following steps:
(1) plate culture: streaking the recombinant engineering bacteria related to the invention on an LB solid plate culture medium containing screening antibiotics, and culturing overnight at 37 ℃;
(2) seed culture: picking a single colony on the plate obtained in the step (1) on an ultra-clean bench, inoculating the single colony into an LB liquid culture medium containing screening antibiotics, and culturing for 8h at 37 ℃;
(3) and (3) induction culture: inoculating the seed culture solution obtained in the step (2) into an LB liquid culture medium containing screening antibiotics on a super clean bench, culturing at 37 ℃ until OD of a bacterial solution is obtained600When the value reaches 0.6, adding IPTG with the final concentration of 0.2mM, and carrying out induced culture at 20 ℃ for 12 h;
(4) and (3) collecting thalli: centrifuging the bacterial liquid obtained by the induced culture in the step (3) for 10min under the condition that the rotating speed is 8000rpm, and separating to obtain thallus sediment; washing the obtained thallus with normal saline for 2 times;
(5) protein purification: and (3) dissolving the thalli obtained in the step (4) in 20mM PBS buffer solution (pH7.4) to obtain cell suspension, performing ultrasonic disruption, centrifuging for 30min under the condition that the rotating speed is 10000rpm, separating to obtain a supernatant crude enzyme solution, and purifying by a nickel column to obtain a completely purified olefinic bond reductase mutant, namely the catalyst.
Preferably, the concentration of the cell suspension in the step (5) is 50 g/L.
Preferably, the ultrasonic crushing power in the step (5) is 200-300W, 5s of ultrasonic treatment, 5s of pause and 99 times of accumulation.
According to the present invention, it was found that position 84 of the wild-type ethylenic reductase plays a key role in both the enhancement of activity and stereoselectivity. Particularly preferably, the olefinic bond reductase mutant Y84V provided by the invention can catalyze citral to prepare (R) -citronellal with high activity and high stereoselectivity, has the characteristics of economy, environmental protection and high chiral selectivity, and provides a potential biocatalyst for industrial production of (R) -citronellal.
Compared with the prior art, the invention has the following beneficial effects:
(1) the olefinic bond reductase mutant Y84V provided by the invention can catalyze high-concentration citral (200mM) to generate (R) -citronellal, the conversion rate is more than 95%, and the ee value of the product (R) -citronellal is more than 95%;
(2) the invention improves the activity and stereoselectivity of the olefinic bond reductase through protein engineering, and has good application prospect in the industrial production of (R) -citronellal.
Drawings
FIG. 1 is a SDS-PAGE protein gel electrophoresis of wild-type ethylenic reductase OYE2P and its mutant Y84V, in which M is protein standard molecular weight, T is whole cell fraction, S is cell disruption supernatant, P is cell disruption precipitate, and E is pure enzyme;
FIG. 2 is a graph of the course of the reaction of wild-type ethylenic reductase OYE2p in catalyzing citral;
FIG. 3 is a graph of the course of the reaction of the ethylenic reductase OYE2p mutant Y84V catalyzing citral.
Detailed Description
The present invention will be further described with reference to the following specific examples. It should be understood that the following examples are illustrative only and are not intended to limit the scope of the present invention. The techniques used in the examples are conventional in the art, as specifically described.
The parent olefinic bond reductase adopted in the specific embodiment is an olefinic bond reductase OYE2p constructed in the early stage of the subject group, the amino acid sequence of the parent olefinic bond reductase is shown as SEQ ID NO.1, and the nucleotide sequence of the parent olefinic bond reductase is shown as SEQ ID NO. 2.
EXAMPLE 1 construction of recombinant E.coli containing mutants
In order to perform site-directed mutagenesis on tyrosine (Tyr) at the 84 th site in the amino acid sequence of parent olefinic bond reductase, mutation sites Y84A, Y84V, Y84L, Y84I, Y84T and Y84C are designed on primers, and plasmids with mutated base sequences are amplified by PCR by using a recombinant plasmid pET21a-OYE2p containing a target gene fragment as a template, and the sequences of the primers are shown in Table 1.
Table 1: primer design sheet
The PCR amplification system was (50. mu.L): template DNA 1-5ng, PrimeSTAR Max Premix (2X) 25. mu.L, mutation primer upstream and downstream each 1.5. mu.L, with sterile distilled water to make up to 50. mu.L.
PCR reaction parameters: (1) pre-denaturation at 98 ℃ for 2 min; (2) denaturation at 95 ℃ for 10 seconds; (3) annealing at 55 ℃ for 5 seconds; (4) extension at 72 ℃ for 2 min, and 30 cycles of steps (2) - (4); (5) extension was completed at 72 ℃ for 5 minutes, and storage was carried out at 16 ℃.
After observing a target band of the PCR product through 1.0% agarose gel electrophoresis, purifying the residual PCR product to obtain a purified linearized plasmid, and taking 50ng of the purified linearized plasmid for seamless cloning.
The seamless cloning system was (20 μ L): linearized plasmid 50ng, Seamless Cloning Mix (2X) 5. mu.L, supplemented to 10. mu.L with sterile distilled water.
The seamless cloning reaction was carried out in a water bath at 50 ℃ for 15 minutes.
The seamless clone product 5. mu.L was taken and transformed into E.coli BL21(DE3) competent cells by heat shock, and then recovered and plated on LB plate containing ampicillin to culture overnight.
Then 5-10 clones are picked to LB culture medium, cultured for 8h at 37 ℃, and then taken bacterial liquid is subjected to sequencing validation to obtain the olefinic bond reductase mutant recombinant engineering bacteria E.coli BL21(DE3)/pET21a-OYE2p/Y84A, E.coli BL21(DE3)/pET21a-OYE2p/Y84V, E.coli BL V (DE V)/pET 21V-OYE 2V/Y84V and E.coli BL V (DE V)/pET 21V-OYE 2V/Y84, and the amino acid sequence of the olefinic bond reductase SEQ ID NO.3 is shown as SEQ ID reductase sequence NO. 3.
Example 2 expression and purification of wild type OYE2p and each mutant
Step 1: the olefinic bond reductase OYE2p obtained in example 1 and the mutant recombinant engineering bacteria were streaked onto LB solid plate medium containing the selected antibiotic, cultured overnight at 37 ℃, single colonies on a single plate were picked up, inoculated into LB liquid medium containing the selected antibiotic, and cultured for 8 hours at 37 ℃. Inoculating the seed culture solution into 200mL LB liquid culture medium containing screening antibiotics, culturing at 37 ℃, adding IPTG with final concentration of 0.2mM when OD600 value of the bacterial solution reaches 0.6, and inducing and culturing at 20 ℃ for 12 h.
Step 2: wild type OYE2p and 6 mutants thereof were purified by immobilized metal ion affinity method using HisTrap from GE as nickel columnTMHP (5 mL). Centrifuging the obtained bacterial liquid for 10min at 8000rpm, separating to obtain thallus precipitate, dissolving the thallus in 20mM PBS buffer (pH7.4) to obtain cell suspension, ultrasonically crushing, centrifuging at 10000rpm for 30min, collecting supernatant, and filtering with 0.22 μm water system filter membrane to obtain crude enzyme liquid.
And step 3: and (3) after the nickel column is balanced by the balance buffer solution, sampling the crude enzyme solution obtained in the step (2), removing foreign proteins by using a low-concentration elution buffer solution, eluting and collecting the target protein by using a high-concentration elution buffer solution, and dialyzing to obtain the pure enzyme. Protein concentration was quantified using the Bradford protein concentration assay kit. The protein purity was checked by SDS-PAGE and the results are shown in FIG. 1, which shows that both wild type and mutant purified to obtain a single protein band.
Example 3 Activity and stereoselectivity of wild type OYE2p and the mutants on citral
The OYE2p obtained in the step 2 of the example 2 and the crude enzyme solution of each mutant expression strain are frozen and dried to prepare freeze-dried crude enzyme powder.
The activity of citral and the ee value of the product were determined by catalyzing the reduction of citral with wild type OYE2p and each mutant in the presence of a uniform amount of enzyme.
The enzyme catalytic reduction reaction system comprises: 100mM phosphate buffer (pH8.5), 15g/L of lyophilized wild type OYE2p and each mutant crude enzyme powder, 5g/L of lyophilized glucose dehydrogenase crude enzyme powder, 20mM citral, 0.2mM NAD+And 100mM glucose. Sequentially adding the substances into a centrifugal tube, placing the centrifugal tube at 200rpm and 30 ℃ for oscillation reaction for 6h, adding equal volume of ethyl acetate to extract twice after the reaction is finished, and combining organic phases for gas phaseAnd (6) detecting.
The results show that the catalytic activity of mutants Y84A, Y84V, Y84L, Y84I, Y84T and Y84C is increased by 25.2%, 40.0%, 25.5%, 34.5%, 24.7% and 33.75% respectively compared with the wild type. And the products of wild type OYE2p and each mutant catalyzing citral are mainly (R) -citronellal, wherein the stereoselectivities of mutants Y84V, Y84L, Y84I and Y84T are respectively improved to 98.0%, 92.1%, 95.5% and 90.1%.
Therefore, the catalytic performance of the mutant obtained by the invention is greatly improved relative to that of the wild-type olefinic bond reductase OYE2p, wherein the mutant Y84V has the best catalytic activity and the highest stereoselectivity.
Example 4 kinetic parameters of wild type OYE2p and its mutant Y84V
The kinetic parameters of the enzyme ethylenic reductase OYE2p and its mutant forms for citral were determined by fixing the concentration of NADH at 0.2mM under standard conditions and varying the concentration of E-citral or Z-citral between 0.01 and 10 mM. The standard detection method is as follows: the total reaction volume was 200. mu.L, 2-20. mu.g of the pure enzyme obtained in example 2 and 10mM substrate were added, 100mM PBS buffer (pH7.4) was added to make up to 196. mu.L, and after incubating at 30 ℃ for 5min with shaking, 4. mu.L of NADH solution (10mM) was added, and the mixture was immediately placed in a microplate reader to measure the change in absorbance at 340 nm. To ensure the accuracy of the experiment, the assay was repeated three times for each sample.
The results show k for E-citral, wild type and Y84V mutantcat/KmThe values are 1.78S respectively-1/mM-1And 3.05S-1/mM-1. K for Z-citral, wild type and Y84V mutantcat/KmThe values are respectively 0.42S-1/mM-1And 0.50S-1/mM-1。
Catalytic efficiency of mutant Y84V for E-citral and Z-citral (k)cat/KmValue) of the amino acid residues ofHas important function.
Example 5 application of wild type OYE2p and its mutant Y84V in catalyzing citral to produce (R) -citronellal
The crude enzyme solution of OYE2p and each mutant expression strain obtained in step 2 of example 2 was freeze-dried to obtain a freeze-dried crude enzyme powder. The reaction system for catalyzing citral by wild type OYE2p and mutant Y84V is as follows: 200mM citral (in DMSO), 0.2mM NAD+250mM glucose, 100mM phosphate buffer (pH8.5), 0.15g of crude lyophilized OYE2p or its mutant Y84V enzyme powder, and 0.05g of crude lyophilized Glucose Dehydrogenase (GDH) enzyme powder, in a total volume of 5 mL. The reaction was carried out in a 25mL Erlenmeyer flask under 30 ℃ with shaking at 200 rpm. During the reaction, Na is added2CO3The pH value of the solution adjusting system is maintained at 8.5.
As shown in FIG. 2, the wild type OYE2p catalyzed 200mM citral for 10h, the conversion reached 91.6%, but the ee value of the product (R) -citronellal formed was only 87.6%. As shown in FIG. 3, the mutant Y84V obtained by the invention has 100% conversion rate after catalyzing 200mM citral for 10h, and the ee value of the product is more than 95%. Therefore, the catalytic performance of the mutant obtained by the invention is greatly improved compared with that of the wild-type olefinic bond reductase OYE2 p.
The above embodiments are merely preferred embodiments of the present invention, which are not intended to limit the scope of the present invention, and various changes may be made in the above embodiments of the present invention. All simple and equivalent changes and modifications made according to the claims and the content of the specification of the present application fall within the scope of the claims of the present invention. The invention has not been described in detail in order to avoid obscuring the invention.
SEQUENCE LISTING
<110> university of east China's college of science
<120> ethylenic reductase mutant with improved activity and stereoselectivity, and coding gene and application thereof
<160> 16
<170> PatentIn version 3.5
<210> 1
<211> 401
<212> PRT
<213> Saccharomyces cerevisiae YJM1341
<400> 1
Met Val Pro Phe Val Lys Asp Phe Lys Pro Gln Ala Leu Gly Asp Thr
1 5 10 15
Asn Leu Phe Lys Pro Ile Lys Ile Gly Asn Asn Glu Leu Leu His Arg
20 25 30
Ala Val Ile Pro Pro Leu Thr Arg Met Arg Ala Gln His Pro Gly Asn
35 40 45
Ile Pro Asn Arg Asp Trp Ala Val Glu Tyr Tyr Ala Gln Arg Ala Gln
50 55 60
Arg Pro Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser Pro Gln
65 70 75 80
Ser Gly Gly Tyr Asp Asn Ala Pro Gly Ile Trp Ser Glu Glu Gln Ile
85 90 95
Lys Glu Trp Thr Lys Ile Phe Lys Ala Ile His Glu Lys Lys Ser Phe
100 105 110
Ala Trp Val Gln Leu Trp Val Leu Gly Trp Ala Ala Phe Pro Asp Thr
115 120 125
Leu Ala Arg Asp Gly Leu Arg Tyr Asp Ser Ala Ser Asp Asn Val Tyr
130 135 140
Met Asn Ala Glu Gln Glu Glu Lys Ala Lys Lys Ala Asn Asn Pro Gln
145 150 155 160
His Ser Ile Thr Lys Asp Glu Ile Lys Gln Tyr Val Lys Glu Tyr Val
165 170 175
Gln Ala Ala Lys Asn Ser Ile Ala Ala Gly Ala Asp Gly Val Glu Ile
180 185 190
His Ser Ala Asn Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro His Ser
195 200 205
Asn Asn Arg Thr Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg Ala Arg
210 215 220
Phe Thr Leu Glu Val Val Asp Ala Val Val Asp Ala Ile Gly Pro Glu
225 230 235 240
Lys Val Gly Leu Arg Leu Ser Pro Tyr Gly Val Phe Asn Ser Met Ser
245 250 255
Gly Gly Ala Glu Thr Gly Ile Val Ala Gln Tyr Ala Tyr Val Leu Gly
260 265 270
Glu Leu Glu Arg Arg Ala Lys Ala Gly Lys Arg Leu Ala Phe Val His
275 280 285
Leu Ile Glu Pro Arg Val Thr Asn Pro Phe Leu Thr Glu Gly Glu Gly
290 295 300
Glu Tyr Asn Gly Gly Ser Asn Glu Phe Ala Tyr Ser Ile Trp Lys Gly
305 310 315 320
Pro Ile Ile Arg Ala Gly Asn Phe Ala Leu His Pro Glu Val Val Arg
325 330 335
Glu Glu Val Lys Asp Pro Arg Thr Leu Ile Gly Tyr Gly Arg Phe Phe
340 345 350
Ile Ser Asn Pro Asp Leu Val Asp Arg Leu Glu Lys Gly Leu Pro Leu
355 360 365
Asn Lys Tyr Asp Arg Asp Thr Phe Tyr Lys Met Ser Ala Glu Gly Tyr
370 375 380
Ile Asp Tyr Pro Thr Tyr Glu Glu Ala Leu Lys Leu Gly Trp Asp Lys
385 390 395 400
Asn
<210> 2
<211> 1203
<212> DNA
<213> Saccharomyces cerevisiae YJM1341
<400> 2
atggttccat ttgttaagga ctttaagcca caagctttgg gtgacaccaa cttattcaaa 60
ccaatcaaaa ttggtaacaa tgaacttcta caccgtgctg tcattcctcc attgactaga 120
atgagagccc aacatccagg taatattcca aacagagact gggccgttga atactacgct 180
caacgtgctc aaagaccagg aaccttgatt atcactgaag gtacctttcc ctctccacaa 240
tctgggggtt acgacaatgc tccaggtatc tggtccgaag aacaaattaa agaatggacc 300
aagattttca aggctattca tgagaagaaa tcgttcgcat gggtccaatt atgggttcta 360
ggttgggctg ctttcccaga cacccttgct agggatggtt tgcgttacga ctccgcttct 420
gacaacgtgt atatgaatgc agaacaagaa gaaaaggcta agaaggctaa caacccacaa 480
cacagtataa caaaggatga aattaagcaa tacgtcaaag aatacgtcca agctgccaaa 540
aactccattg ctgctggtgc cgatggtgtt gaaatccaca gcgctaacgg ttacttgttg 600
aaccagttct tggacccaca ctccaataac agaaccgatg agtatggtgg atccatcgaa 660
aacagagccc gtttcacctt ggaagtggtt gatgcagttg tcgatgctat tggccctgaa 720
aaagtcggtt tgagattgtc tccatatggt gtcttcaaca gtatgtctgg tggtgctgaa 780
accggtattg ttgctcaata tgcttatgtc ttaggtgaac tagaaagaag agctaaagct 840
ggcaagcgtt tggctttcgt ccatctaatt gaacctcgtg tcaccaaccc atttttaact 900
gaaggtgaag gtgaatacaa tggaggtagc aacgaatttg cttattctat ctggaagggc 960
ccaattatta gagctggtaa ctttgctctg cacccagaag ttgtcagaga agaggtgaag 1020
gatcctagaa cattgatcgg ttacggtaga ttttttatct ctaatccaga tttggttgat 1080
cgtttggaaa aagggttacc attaaacaaa tatgacagag acactttcta caaaatgtca 1140
gctgagggat acattgacta ccctacgtac gaagaagctc taaaactcgg ttgggacaaa 1200
aat 1203
<210> 3
<211> 401
<212> PRT
<213> Artificial sequence
<400> 3
Met Val Pro Phe Val Lys Asp Phe Lys Pro Gln Ala Leu Gly Asp Thr
1 5 10 15
Asn Leu Phe Lys Pro Ile Lys Ile Gly Asn Asn Glu Leu Leu His Arg
20 25 30
Ala Val Ile Pro Pro Leu Thr Arg Met Arg Ala Gln His Pro Gly Asn
35 40 45
Ile Pro Asn Arg Asp Trp Ala Val Glu Tyr Tyr Ala Gln Arg Ala Gln
50 55 60
Arg Pro Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser Pro Gln
65 70 75 80
Ser Gly Gly Ala Asp Asn Ala Pro Gly Ile Trp Ser Glu Glu Gln Ile
85 90 95
Lys Glu Trp Thr Lys Ile Phe Lys Ala Ile His Glu Lys Lys Ser Phe
100 105 110
Ala Trp Val Gln Leu Trp Val Leu Gly Trp Ala Ala Phe Pro Asp Thr
115 120 125
Leu Ala Arg Asp Gly Leu Arg Tyr Asp Ser Ala Ser Asp Asn Val Tyr
130 135 140
Met Asn Ala Glu Gln Glu Glu Lys Ala Lys Lys Ala Asn Asn Pro Gln
145 150 155 160
His Ser Ile Thr Lys Asp Glu Ile Lys Gln Tyr Val Lys Glu Tyr Val
165 170 175
Gln Ala Ala Lys Asn Ser Ile Ala Ala Gly Ala Asp Gly Val Glu Ile
180 185 190
His Ser Ala Asn Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro His Ser
195 200 205
Asn Asn Arg Thr Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg Ala Arg
210 215 220
Phe Thr Leu Glu Val Val Asp Ala Val Val Asp Ala Ile Gly Pro Glu
225 230 235 240
Lys Val Gly Leu Arg Leu Ser Pro Tyr Gly Val Phe Asn Ser Met Ser
245 250 255
Gly Gly Ala Glu Thr Gly Ile Val Ala Gln Tyr Ala Tyr Val Leu Gly
260 265 270
Glu Leu Glu Arg Arg Ala Lys Ala Gly Lys Arg Leu Ala Phe Val His
275 280 285
Leu Ile Glu Pro Arg Val Thr Asn Pro Phe Leu Thr Glu Gly Glu Gly
290 295 300
Glu Tyr Asn Gly Gly Ser Asn Glu Phe Ala Tyr Ser Ile Trp Lys Gly
305 310 315 320
Pro Ile Ile Arg Ala Gly Asn Phe Ala Leu His Pro Glu Val Val Arg
325 330 335
Glu Glu Val Lys Asp Pro Arg Thr Leu Ile Gly Tyr Gly Arg Phe Phe
340 345 350
Ile Ser Asn Pro Asp Leu Val Asp Arg Leu Glu Lys Gly Leu Pro Leu
355 360 365
Asn Lys Tyr Asp Arg Asp Thr Phe Tyr Lys Met Ser Ala Glu Gly Tyr
370 375 380
Ile Asp Tyr Pro Thr Tyr Glu Glu Ala Leu Lys Leu Gly Trp Asp Lys
385 390 395 400
Asn
<210> 4
<211> 400
<212> PRT
<213> Artificial sequence
<400> 4
Met Val Pro Phe Val Lys Asp Phe Lys Pro Gln Ala Leu Gly Asp Thr
1 5 10 15
Asn Leu Phe Lys Pro Ile Lys Ile Gly Asn Asn Glu Leu Leu His Arg
20 25 30
Ala Val Ile Pro Pro Leu Thr Arg Met Arg Ala Gln His Pro Gly Asn
35 40 45
Ile Pro Asn Arg Asp Trp Ala Val Glu Tyr Tyr Ala Gln Arg Ala Gln
50 55 60
Arg Pro Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser Pro Gln
65 70 75 80
Ser Gly Gly Val Asn Ala Pro Gly Ile Trp Ser Glu Glu Gln Ile Lys
85 90 95
Glu Trp Thr Lys Ile Phe Lys Ala Ile His Glu Lys Lys Ser Phe Ala
100 105 110
Trp Val Gln Leu Trp Val Leu Gly Trp Ala Ala Phe Pro Asp Thr Leu
115 120 125
Ala Arg Asp Gly Leu Arg Tyr Asp Ser Ala Ser Asp Asn Val Tyr Met
130 135 140
Asn Ala Glu Gln Glu Glu Lys Ala Lys Lys Ala Asn Asn Pro Gln His
145 150 155 160
Ser Ile Thr Lys Asp Glu Ile Lys Gln Tyr Val Lys Glu Tyr Val Gln
165 170 175
Ala Ala Lys Asn Ser Ile Ala Ala Gly Ala Asp Gly Val Glu Ile His
180 185 190
Ser Ala Asn Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro His Ser Asn
195 200 205
Asn Arg Thr Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg Ala Arg Phe
210 215 220
Thr Leu Glu Val Val Asp Ala Val Val Asp Ala Ile Gly Pro Glu Lys
225 230 235 240
Val Gly Leu Arg Leu Ser Pro Tyr Gly Val Phe Asn Ser Met Ser Gly
245 250 255
Gly Ala Glu Thr Gly Ile Val Ala Gln Tyr Ala Tyr Val Leu Gly Glu
260 265 270
Leu Glu Arg Arg Ala Lys Ala Gly Lys Arg Leu Ala Phe Val His Leu
275 280 285
Ile Glu Pro Arg Val Thr Asn Pro Phe Leu Thr Glu Gly Glu Gly Glu
290 295 300
Tyr Asn Gly Gly Ser Asn Glu Phe Ala Tyr Ser Ile Trp Lys Gly Pro
305 310 315 320
Ile Ile Arg Ala Gly Asn Phe Ala Leu His Pro Glu Val Val Arg Glu
325 330 335
Glu Val Lys Asp Pro Arg Thr Leu Ile Gly Tyr Gly Arg Phe Phe Ile
340 345 350
Ser Asn Pro Asp Leu Val Asp Arg Leu Glu Lys Gly Leu Pro Leu Asn
355 360 365
Lys Tyr Asp Arg Asp Thr Phe Tyr Lys Met Ser Ala Glu Gly Tyr Ile
370 375 380
Asp Tyr Pro Thr Tyr Glu Glu Ala Leu Lys Leu Gly Trp Asp Lys Asn
385 390 395 400
<210> 5
<211> 399
<212> PRT
<213> Artificial sequence
<400> 5
Met Val Pro Phe Val Lys Asp Phe Lys Pro Gln Ala Leu Gly Asp Thr
1 5 10 15
Asn Leu Phe Lys Pro Ile Lys Ile Gly Asn Asn Glu Leu Leu His Arg
20 25 30
Ala Val Ile Pro Pro Leu Thr Arg Met Arg Ala Gln His Pro Gly Asn
35 40 45
Ile Pro Asn Arg Asp Trp Ala Val Glu Tyr Tyr Ala Gln Arg Ala Gln
50 55 60
Arg Pro Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser Pro Gln
65 70 75 80
Ser Gly Gly Leu Ala Pro Gly Ile Trp Ser Glu Glu Gln Ile Lys Glu
85 90 95
Trp Thr Lys Ile Phe Lys Ala Ile His Glu Lys Lys Ser Phe Ala Trp
100 105 110
Val Gln Leu Trp Val Leu Gly Trp Ala Ala Phe Pro Asp Thr Leu Ala
115 120 125
Arg Asp Gly Leu Arg Tyr Asp Ser Ala Ser Asp Asn Val Tyr Met Asn
130 135 140
Ala Glu Gln Glu Glu Lys Ala Lys Lys Ala Asn Asn Pro Gln His Ser
145 150 155 160
Ile Thr Lys Asp Glu Ile Lys Gln Tyr Val Lys Glu Tyr Val Gln Ala
165 170 175
Ala Lys Asn Ser Ile Ala Ala Gly Ala Asp Gly Val Glu Ile His Ser
180 185 190
Ala Asn Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro His Ser Asn Asn
195 200 205
Arg Thr Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg Ala Arg Phe Thr
210 215 220
Leu Glu Val Val Asp Ala Val Val Asp Ala Ile Gly Pro Glu Lys Val
225 230 235 240
Gly Leu Arg Leu Ser Pro Tyr Gly Val Phe Asn Ser Met Ser Gly Gly
245 250 255
Ala Glu Thr Gly Ile Val Ala Gln Tyr Ala Tyr Val Leu Gly Glu Leu
260 265 270
Glu Arg Arg Ala Lys Ala Gly Lys Arg Leu Ala Phe Val His Leu Ile
275 280 285
Glu Pro Arg Val Thr Asn Pro Phe Leu Thr Glu Gly Glu Gly Glu Tyr
290 295 300
Asn Gly Gly Ser Asn Glu Phe Ala Tyr Ser Ile Trp Lys Gly Pro Ile
305 310 315 320
Ile Arg Ala Gly Asn Phe Ala Leu His Pro Glu Val Val Arg Glu Glu
325 330 335
Val Lys Asp Pro Arg Thr Leu Ile Gly Tyr Gly Arg Phe Phe Ile Ser
340 345 350
Asn Pro Asp Leu Val Asp Arg Leu Glu Lys Gly Leu Pro Leu Asn Lys
355 360 365
Tyr Asp Arg Asp Thr Phe Tyr Lys Met Ser Ala Glu Gly Tyr Ile Asp
370 375 380
Tyr Pro Thr Tyr Glu Glu Ala Leu Lys Leu Gly Trp Asp Lys Asn
385 390 395
<210> 6
<211> 398
<212> PRT
<213> Artificial sequence
<400> 6
Met Val Pro Phe Val Lys Asp Phe Lys Pro Gln Ala Leu Gly Asp Thr
1 5 10 15
Asn Leu Phe Lys Pro Ile Lys Ile Gly Asn Asn Glu Leu Leu His Arg
20 25 30
Ala Val Ile Pro Pro Leu Thr Arg Met Arg Ala Gln His Pro Gly Asn
35 40 45
Ile Pro Asn Arg Asp Trp Ala Val Glu Tyr Tyr Ala Gln Arg Ala Gln
50 55 60
Arg Pro Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser Pro Gln
65 70 75 80
Ser Gly Gly Ile Pro Gly Ile Trp Ser Glu Glu Gln Ile Lys Glu Trp
85 90 95
Thr Lys Ile Phe Lys Ala Ile His Glu Lys Lys Ser Phe Ala Trp Val
100 105 110
Gln Leu Trp Val Leu Gly Trp Ala Ala Phe Pro Asp Thr Leu Ala Arg
115 120 125
Asp Gly Leu Arg Tyr Asp Ser Ala Ser Asp Asn Val Tyr Met Asn Ala
130 135 140
Glu Gln Glu Glu Lys Ala Lys Lys Ala Asn Asn Pro Gln His Ser Ile
145 150 155 160
Thr Lys Asp Glu Ile Lys Gln Tyr Val Lys Glu Tyr Val Gln Ala Ala
165 170 175
Lys Asn Ser Ile Ala Ala Gly Ala Asp Gly Val Glu Ile His Ser Ala
180 185 190
Asn Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro His Ser Asn Asn Arg
195 200 205
Thr Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg Ala Arg Phe Thr Leu
210 215 220
Glu Val Val Asp Ala Val Val Asp Ala Ile Gly Pro Glu Lys Val Gly
225 230 235 240
Leu Arg Leu Ser Pro Tyr Gly Val Phe Asn Ser Met Ser Gly Gly Ala
245 250 255
Glu Thr Gly Ile Val Ala Gln Tyr Ala Tyr Val Leu Gly Glu Leu Glu
260 265 270
Arg Arg Ala Lys Ala Gly Lys Arg Leu Ala Phe Val His Leu Ile Glu
275 280 285
Pro Arg Val Thr Asn Pro Phe Leu Thr Glu Gly Glu Gly Glu Tyr Asn
290 295 300
Gly Gly Ser Asn Glu Phe Ala Tyr Ser Ile Trp Lys Gly Pro Ile Ile
305 310 315 320
Arg Ala Gly Asn Phe Ala Leu His Pro Glu Val Val Arg Glu Glu Val
325 330 335
Lys Asp Pro Arg Thr Leu Ile Gly Tyr Gly Arg Phe Phe Ile Ser Asn
340 345 350
Pro Asp Leu Val Asp Arg Leu Glu Lys Gly Leu Pro Leu Asn Lys Tyr
355 360 365
Asp Arg Asp Thr Phe Tyr Lys Met Ser Ala Glu Gly Tyr Ile Asp Tyr
370 375 380
Pro Thr Tyr Glu Glu Ala Leu Lys Leu Gly Trp Asp Lys Asn
385 390 395
<210> 7
<211> 397
<212> PRT
<213> Artificial sequence
<400> 7
Met Val Pro Phe Val Lys Asp Phe Lys Pro Gln Ala Leu Gly Asp Thr
1 5 10 15
Asn Leu Phe Lys Pro Ile Lys Ile Gly Asn Asn Glu Leu Leu His Arg
20 25 30
Ala Val Ile Pro Pro Leu Thr Arg Met Arg Ala Gln His Pro Gly Asn
35 40 45
Ile Pro Asn Arg Asp Trp Ala Val Glu Tyr Tyr Ala Gln Arg Ala Gln
50 55 60
Arg Pro Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser Pro Gln
65 70 75 80
Ser Gly Gly Thr Gly Ile Trp Ser Glu Glu Gln Ile Lys Glu Trp Thr
85 90 95
Lys Ile Phe Lys Ala Ile His Glu Lys Lys Ser Phe Ala Trp Val Gln
100 105 110
Leu Trp Val Leu Gly Trp Ala Ala Phe Pro Asp Thr Leu Ala Arg Asp
115 120 125
Gly Leu Arg Tyr Asp Ser Ala Ser Asp Asn Val Tyr Met Asn Ala Glu
130 135 140
Gln Glu Glu Lys Ala Lys Lys Ala Asn Asn Pro Gln His Ser Ile Thr
145 150 155 160
Lys Asp Glu Ile Lys Gln Tyr Val Lys Glu Tyr Val Gln Ala Ala Lys
165 170 175
Asn Ser Ile Ala Ala Gly Ala Asp Gly Val Glu Ile His Ser Ala Asn
180 185 190
Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro His Ser Asn Asn Arg Thr
195 200 205
Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg Ala Arg Phe Thr Leu Glu
210 215 220
Val Val Asp Ala Val Val Asp Ala Ile Gly Pro Glu Lys Val Gly Leu
225 230 235 240
Arg Leu Ser Pro Tyr Gly Val Phe Asn Ser Met Ser Gly Gly Ala Glu
245 250 255
Thr Gly Ile Val Ala Gln Tyr Ala Tyr Val Leu Gly Glu Leu Glu Arg
260 265 270
Arg Ala Lys Ala Gly Lys Arg Leu Ala Phe Val His Leu Ile Glu Pro
275 280 285
Arg Val Thr Asn Pro Phe Leu Thr Glu Gly Glu Gly Glu Tyr Asn Gly
290 295 300
Gly Ser Asn Glu Phe Ala Tyr Ser Ile Trp Lys Gly Pro Ile Ile Arg
305 310 315 320
Ala Gly Asn Phe Ala Leu His Pro Glu Val Val Arg Glu Glu Val Lys
325 330 335
Asp Pro Arg Thr Leu Ile Gly Tyr Gly Arg Phe Phe Ile Ser Asn Pro
340 345 350
Asp Leu Val Asp Arg Leu Glu Lys Gly Leu Pro Leu Asn Lys Tyr Asp
355 360 365
Arg Asp Thr Phe Tyr Lys Met Ser Ala Glu Gly Tyr Ile Asp Tyr Pro
370 375 380
Thr Tyr Glu Glu Ala Leu Lys Leu Gly Trp Asp Lys Asn
385 390 395
<210> 8
<211> 396
<212> PRT
<213> Artificial sequence
<400> 8
Met Val Pro Phe Val Lys Asp Phe Lys Pro Gln Ala Leu Gly Asp Thr
1 5 10 15
Asn Leu Phe Lys Pro Ile Lys Ile Gly Asn Asn Glu Leu Leu His Arg
20 25 30
Ala Val Ile Pro Pro Leu Thr Arg Met Arg Ala Gln His Pro Gly Asn
35 40 45
Ile Pro Asn Arg Asp Trp Ala Val Glu Tyr Tyr Ala Gln Arg Ala Gln
50 55 60
Arg Pro Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser Pro Gln
65 70 75 80
Ser Gly Gly Cys Ile Trp Ser Glu Glu Gln Ile Lys Glu Trp Thr Lys
85 90 95
Ile Phe Lys Ala Ile His Glu Lys Lys Ser Phe Ala Trp Val Gln Leu
100 105 110
Trp Val Leu Gly Trp Ala Ala Phe Pro Asp Thr Leu Ala Arg Asp Gly
115 120 125
Leu Arg Tyr Asp Ser Ala Ser Asp Asn Val Tyr Met Asn Ala Glu Gln
130 135 140
Glu Glu Lys Ala Lys Lys Ala Asn Asn Pro Gln His Ser Ile Thr Lys
145 150 155 160
Asp Glu Ile Lys Gln Tyr Val Lys Glu Tyr Val Gln Ala Ala Lys Asn
165 170 175
Ser Ile Ala Ala Gly Ala Asp Gly Val Glu Ile His Ser Ala Asn Gly
180 185 190
Tyr Leu Leu Asn Gln Phe Leu Asp Pro His Ser Asn Asn Arg Thr Asp
195 200 205
Glu Tyr Gly Gly Ser Ile Glu Asn Arg Ala Arg Phe Thr Leu Glu Val
210 215 220
Val Asp Ala Val Val Asp Ala Ile Gly Pro Glu Lys Val Gly Leu Arg
225 230 235 240
Leu Ser Pro Tyr Gly Val Phe Asn Ser Met Ser Gly Gly Ala Glu Thr
245 250 255
Gly Ile Val Ala Gln Tyr Ala Tyr Val Leu Gly Glu Leu Glu Arg Arg
260 265 270
Ala Lys Ala Gly Lys Arg Leu Ala Phe Val His Leu Ile Glu Pro Arg
275 280 285
Val Thr Asn Pro Phe Leu Thr Glu Gly Glu Gly Glu Tyr Asn Gly Gly
290 295 300
Ser Asn Glu Phe Ala Tyr Ser Ile Trp Lys Gly Pro Ile Ile Arg Ala
305 310 315 320
Gly Asn Phe Ala Leu His Pro Glu Val Val Arg Glu Glu Val Lys Asp
325 330 335
Pro Arg Thr Leu Ile Gly Tyr Gly Arg Phe Phe Ile Ser Asn Pro Asp
340 345 350
Leu Val Asp Arg Leu Glu Lys Gly Leu Pro Leu Asn Lys Tyr Asp Arg
355 360 365
Asp Thr Phe Tyr Lys Met Ser Ala Glu Gly Tyr Ile Asp Tyr Pro Thr
370 375 380
Tyr Glu Glu Ala Leu Lys Leu Gly Trp Asp Lys Asn
385 390 395
<210> 9
<211> 1203
<212> DNA
<213> Artificial sequence
<400> 9
atggttccat ttgttaagga ctttaagcca caagctttgg gtgacaccaa cttattcaaa 60
ccaatcaaaa ttggtaacaa tgaacttcta caccgtgctg tcattcctcc attgactaga 120
atgagagccc aacatccagg taatattcca aacagagact gggccgttga atactacgct 180
caacgtgctc aaagaccagg aaccttgatt atcactgaag gtacctttcc ctctccacaa 240
tctgggggtg ttgacaatgc tccaggtatc tggtccgaag aacaaattaa agaatggacc 300
aagattttca aggctattca tgagaagaaa tcgttcgcat gggtccaatt atgggttcta 360
ggttgggctg ctttcccaga cacccttgct agggatggtt tgcgttacga ctccgcttct 420
gacaacgtgt atatgaatgc agaacaagaa gaaaaggcta agaaggctaa caacccacaa 480
cacagtataa caaaggatga aattaagcaa tacgtcaaag aatacgtcca agctgccaaa 540
aactccattg ctgctggtgc cgatggtgtt gaaatccaca gcgctaacgg ttacttgttg 600
aaccagttct tggacccaca ctccaataac agaaccgatg agtatggtgg atccatcgaa 660
aacagagccc gtttcacctt ggaagtggtt gatgcagttg tcgatgctat tggccctgaa 720
aaagtcggtt tgagattgtc tccatatggt gtcttcaaca gtatgtctgg tggtgctgaa 780
accggtattg ttgctcaata tgcttatgtc ttaggtgaac tagaaagaag agctaaagct 840
ggcaagcgtt tggctttcgt ccatctaatt gaacctcgtg tcaccaaccc atttttaact 900
gaaggtgaag gtgaatacaa tggaggtagc aacgaatttg cttattctat ctggaagggc 960
ccaattatta gagctggtaa ctttgctctg cacccagaag ttgtcagaga agaggtgaag 1020
gatcctagaa cattgatcgg ttacggtaga ttttttatct ctaatccaga tttggttgat 1080
cgtttggaaa aagggttacc attaaacaaa tatgacagag acactttcta caaaatgtca 1140
gctgagggat acattgacta ccctacgtac gaagaagctc taaaactcgg ttgggacaaa 1200
aat 1203
<210> 10
<211> 20
<212> DNA
<213> Artificial sequence
<400> 10
acccccagat tgtggagagg 20
<210> 11
<211> 43
<212> DNA
<213> Artificial sequence
<400> 11
cctctccaca atctgggggt gccgacaatg ctccaggtat ctg 43
<210> 12
<211> 43
<212> DNA
<213> Artificial sequence
<400> 12
cctctccaca atctgggggt gttgacaatg ctccaggtat ctg 43
<210> 13
<211> 43
<212> DNA
<213> Artificial sequence
<400> 13
cctctccaca atctgggggt ttggacaatg ctccaggtat ctg 43
<210> 14
<211> 43
<212> DNA
<213> Artificial sequence
<400> 14
cctctccaca atctgggggt attgacaatg ctccaggtat ctg 43
<210> 15
<211> 43
<212> DNA
<213> Artificial sequence
<400> 15
cctctccaca atctgggggt accgacaatg ctccaggtat ctg 43
<210> 16
<211> 43
<212> DNA
<213> Artificial sequence
<400> 16
cctctccaca atctgggggt tgtgacaatg ctccaggtat ctg 43
Claims (9)
1. An olefinic bond reductase mutant with improved activity and stereoselectivity, which is characterized by comprising an olefinic bond reductase mutant formed by taking a wild type olefinic bond reductase OYE2p shown in SEQ ID NO.1 as a template and carrying out the following mutations on amino acid residues at position 84:
the tyrosine Y at the 84 th position is mutated into an olefinic bond reductase mutant Y84A of alanine A, and the amino acid sequence is shown as SEQ ID NO. 3;
an olefinic bond reductase mutant Y84V with the mutation of tyrosine Y at the 84 th position into valine V and the amino acid sequence shown as SEQ ID NO. 4;
an olefinic bond reductase mutant Y84L with the 84 th tyrosine Y mutated into leucine L and the amino acid sequence shown as SEQ ID NO. 5;
tyrosine Y at the 84 th position is mutated into an olefinic bond reductase mutant Y84I of isoleucine I, and the amino acid sequence is shown as SEQ ID NO. 6;
an olefinic bond reductase mutant Y84T with the 84 th tyrosine Y mutated into threonine T and the amino acid sequence shown as SEQ ID NO. 7;
tyrosine Y at the 84 th position is mutated into an olefinic bond reductase mutant Y84C of cysteine C, and the amino acid sequence is shown as SEQ ID NO. 8.
2. A gene encoding an olefinic bond reductase mutant, wherein the gene encodes the amino acid sequence of any one of the olefinic bond reductase mutants of claim 1.
3. A recombinant genetically engineered bacterium comprising a gene encoding the ethylenic reductase mutant of claim 2.
4. The recombinant genetically engineered bacterium of claim 3, wherein the recombinant genetically engineered bacterium is a host bacterium of Escherichia coli.
5. Use of the mutant of an ethylenic reductase according to claim 1 for catalyzing citral to produce (R) -citronellal.
6. The use of claim 5, wherein the use comprises the preparation of (R) -citronellal from citral catalyzed by a recombinant genetically engineered bacterium containing a gene encoding an olefinic bond reductase mutant.
7. The application of claim 6, wherein the application comprises: the method comprises the steps of taking thalli obtained by centrifuging recombinant genetic engineering bacteria containing olefinic bond reductase mutant coding genes after fermentation culture, thalli immobilized cells, enzyme extracted after ultrasonic disruption of the thalli, immobilized enzyme or pure enzyme as a catalyst, taking citral as a substrate, taking a buffer solution with the pH of 7-9 as a reaction medium, reacting at the temperature of 20-40 ℃ and under the condition of 300R/min, and after the reaction is finished, separating and purifying a reaction liquid to obtain (R) -citronellal.
8. The use according to claim 7, wherein the substrate concentration in the reaction system is 20 to 200mM, the glucose concentration is 30 to 220mM, the amount of the ethylenic reductase to be used is 1 to 5U/mL in terms of the enzyme activity, and the amount of the glucose dehydrogenase to be used is 1.5 to 7.5U/mL in terms of the enzyme activity.
9. Use according to claim 8, wherein the reaction is carried out by adding Na, depending on the pH change2CO3The solution was adjusted to pH 8.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110674324.3A CN113481175B (en) | 2021-06-17 | 2021-06-17 | Active and stereoselectivity improved olefinic bond reductase mutant and encoding gene and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110674324.3A CN113481175B (en) | 2021-06-17 | 2021-06-17 | Active and stereoselectivity improved olefinic bond reductase mutant and encoding gene and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113481175A true CN113481175A (en) | 2021-10-08 |
| CN113481175B CN113481175B (en) | 2023-07-14 |
Family
ID=77935503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110674324.3A Active CN113481175B (en) | 2021-06-17 | 2021-06-17 | Active and stereoselectivity improved olefinic bond reductase mutant and encoding gene and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113481175B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101186924A (en) * | 2007-11-30 | 2008-05-28 | 华东理工大学 | Gene engineering bacterium for catalyzing citral to produce citronellal and construction method thereof |
| US20100190218A1 (en) * | 2008-12-25 | 2010-07-29 | Codexis, Inc. | Enone reductases |
| WO2018183706A1 (en) * | 2017-03-29 | 2018-10-04 | University Of Florida Research Foundation, Inc. | Materials and methods for alkene reduction of levoglucosenone by an alkene reductase |
| CN109957602A (en) * | 2017-12-14 | 2019-07-02 | 中国科学院大连化学物理研究所 | A kind of screening technique of NAD analog preference type oxidoreducing enzyme |
| CN111454918A (en) * | 2020-03-10 | 2020-07-28 | 浙江工业大学 | Enol reductase mutant and application thereof in preparation of (R) -citronellal |
| CN112553097A (en) * | 2020-11-26 | 2021-03-26 | 天津大学 | Yeast gene engineering strain for high yield of citronellol and construction method and fermentation method thereof |
-
2021
- 2021-06-17 CN CN202110674324.3A patent/CN113481175B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101186924A (en) * | 2007-11-30 | 2008-05-28 | 华东理工大学 | Gene engineering bacterium for catalyzing citral to produce citronellal and construction method thereof |
| US20100190218A1 (en) * | 2008-12-25 | 2010-07-29 | Codexis, Inc. | Enone reductases |
| WO2018183706A1 (en) * | 2017-03-29 | 2018-10-04 | University Of Florida Research Foundation, Inc. | Materials and methods for alkene reduction of levoglucosenone by an alkene reductase |
| CN109957602A (en) * | 2017-12-14 | 2019-07-02 | 中国科学院大连化学物理研究所 | A kind of screening technique of NAD analog preference type oxidoreducing enzyme |
| CN111454918A (en) * | 2020-03-10 | 2020-07-28 | 浙江工业大学 | Enol reductase mutant and application thereof in preparation of (R) -citronellal |
| CN112553097A (en) * | 2020-11-26 | 2021-03-26 | 天津大学 | Yeast gene engineering strain for high yield of citronellol and construction method and fermentation method thereof |
Non-Patent Citations (8)
Also Published As
| Publication number | Publication date |
|---|---|
| CN113481175B (en) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111269900B (en) | Preparation and application of L-amino acid deaminase mutant | |
| CN109055327B (en) | Aldehyde ketone reductase mutant and application thereof | |
| CN108467860B (en) | Method for high yield of gamma-aminobutyric acid | |
| CN108048438B (en) | Halohydrin dehalogenase mutant and application thereof | |
| CN112877307B (en) | Amino acid dehydrogenase mutant and application thereof | |
| CN102277338A (en) | Diketoreductase mutant and application thereof | |
| CN112941043B (en) | Carbonyl reductase mutant and application thereof in preparation of chiral beta' -hydroxy-beta-amino acid ester | |
| CN109504645B (en) | Isoleucine dioxygenase, mutant and application in synthesis of 4-hydroxyisoleucine | |
| CN109468291B (en) | Carbonyl reductase EbSDR8 mutant and construction method and application thereof | |
| CN109055324B (en) | Improved ketoreductase and application thereof | |
| CN109777788B (en) | Leucine dehydrogenase mutant and application thereof | |
| CN113462678B (en) | Glutamic acid decarboxylase mutant | |
| CN111454918B (en) | Enol reductase mutant and application thereof in preparation of (R) -citronellal | |
| CN111004787B (en) | Streptomyces phospholipase D mutant, transformation method and application thereof | |
| CN110592035B (en) | Carbonyl reductase mutant, recombinant expression vector and application of carbonyl reductase mutant in production of chiral alcohol | |
| CN109593739B (en) | Recombinant ketoacid reductase mutant, gene, engineering bacterium and application thereof | |
| CN110129305B (en) | Cephalosporin C acylase mutant for preparing 7-ACA | |
| CN115433721B (en) | Carbonyl reductase mutant and application thereof | |
| CN114410562B (en) | Klebsiella engineering bacterium and application thereof in ethanol production | |
| CN113481175B (en) | Active and stereoselectivity improved olefinic bond reductase mutant and encoding gene and application thereof | |
| CN112410353B (en) | fkbS gene, genetic engineering bacterium containing fkbS gene, and preparation method and application of fkbS gene | |
| CN113355366A (en) | Method for preparing 2-phenethyl alcohol by multi-enzyme cascade | |
| CN106047826B (en) | Aldehyde dehydrogenase, its recombinant expression transformants and the application in the synthesis of statin precursor | |
| WO2005123921A1 (en) | Novel glycerol dehydrogenase, gene therefor, and method of utilizing the same | |
| CN114410599B (en) | Carbonyl reductase mutant and application thereof in preparation of rosuvastatin chiral intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |